Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
167 hedge funds and large institutions have $1.43B invested in Aerie Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 79 increasing their positions, 39 reducing their positions, and 36 closing their positions.
103% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 39
34% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $11.8M
5% less funds holding
Funds holding: 176 → 167 (-9)
19% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 36
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
37% less capital invested
Capital invested by funds: $2.26B → $1.43B (-$826M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$54.9M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$15M |
| 3 |
BlackRock
New York
|
+$12.8M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$12.3M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$9.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.4M |
| 2 |
Jennison Associates
New York
|
-$21M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$20.8M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$13.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.07M |
AERI Hedge Fund Activity: Q2 2019 in Review
167 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2019, worth a combined $1.43B — down 37% from $2.26B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AERI and 29 opened new positions — a net loss of 7 holders — while 39 trimmed existing stakes and 79 added.
The largest buyer was Deerfield Management, adding an estimated $54.9M. The largest seller was Adage Capital Partners, cutting an estimated $21.4M.
- 167 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2019, down from 176 in Q1 2019.
- Funds reported $1.43B of Aerie Pharmaceuticals stock for Q2 2019, down 37% quarter-over-quarter.
- 29 funds opened new Aerie Pharmaceuticals positions in Q2 2019 and 36 closed out, a net change of -7 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2019 was Deerfield Management, an estimated $54.9M added.
- The largest Aerie Pharmaceuticals seller in Q2 2019 was Adage Capital Partners, an estimated $21.4M sold.
Based on aggregated 13F filings for Q2 2019.